Characteristics | 2–5 y | 5–10 y | 10–18 y | Total | P value | ||||
---|---|---|---|---|---|---|---|---|---|
(N = 18) | (N = 83) | (N = 153) | (N = 254) | ||||||
Study site | 0.79 | ||||||||
Albert Royer Hospital | 13 | (72) | 61 | (73) | 106 | (69) | 180 | (71) | |
Roi Baudouin Hospital | 5 | (28) | 22 | (27) | 47 | (31) | 74 | (29) | |
Girls | 6 | (33) | 37 | (45) | 68 | (44) | 111 | (44) | 0.65 |
WHO classificationc | 0.03 | ||||||||
Stage 1–2 | 8 | (44) | 14 | (17) | 29 | (19) | 51 | (20) | |
Stage 3–4 | 10 | (56) | 69 | (83) | 124 | (81) | 203 | (80) | |
Moderate wastingd | 0 | – | 14 | (17) | 49 | (32) | 63 | (25) | 0.002 |
WHZ/BMIZ, median (IQR) | −0.7 | (−1.6–0.2) | −1.1 | (−1.8 – −0.4) | −1.6 | (−2.2 – − 0.9) | −1.4 | (−2.0 – − 0.7) | < 0.0001 |
HAZ, median (IQR) | − 1.3 | (−2.0 – − 1.0) | −1.1 | (− 1.7 – − 0.3) | −1.2 | (− 1.9 – − 0.5) | −1.2 | (− 1.8 – − 0.5) | 0.37 |
Puberty onset | 0 | – | 0 | – | 92 | (60) | 92 | (36) | < 0.0001 |
CD4 < 500 cells/mm3 | 2 | (11) | 7 | (9) | 38 | (25) | 47 | (19) | 0.01 |
Viral load < 40 copies/mL | 7 | (39) | 57 | (70) | 108 | (71) | 172 | (68) | 0.02 |
Time on ART in month, median (IQR) | 22 | (11–30) | 47 | (31–61) | 64 | (34–100) | 54 | (32–84) | < 0.0001 |
ARV drug classes | |||||||||
2NRTI/NNRTI | 15 | (83) | 65 | (78) | 72 | (47) | 152 | (60) | |
2NRTI/PI | 3 | (17) | 15 | (18) | 28 | (18) | 46 | (18) | |
NRTI/NNRTI/nRTI | 0 | – | 1 | (1) | 30 | (20) | 31 | (12) | |
NRTI/nRTI/PI | 0 | – | 2 | (3) | 22 | (14) | 24 | (10) | |
NRTI/nRTI/PI/II | 0 | – | 0 | – | 1 | (1) | 1 | (0) |